Overview

Bevacizumab and Vasoconstriction

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.
Phase:
N/A
Details
Lead Sponsor:
Radboud University
Treatments:
Bevacizumab